Enhancing Survival Through Innovative Immune Modulation

We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.

See News
Menu

Corporate profile

We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma has reached a major milestone in its development in January 2025, with positive topline results from its Phase 3 clinical trial evaluating its microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Press Releases

Press Releases

September 17, 2025: MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update

MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results…
Press Releases
July 28, 2025: MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
Press Releases
July 24, 2025: MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux
Press Releases
July 7, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
July 2nd, 2025: MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

See more

Media Coverage

Media

September 22, 2025: Interview of Eric Soyer, CFO at MaaT Pharma (French Only)

Media
August 7, 2025: French Tech : Maat Pharma traite les complications de greffe de moelle osseuse – BFM Business (French Only)
Media
July 21, 2025: World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings – Citeline
Media
June 25, 2025: Just the Two of Us: Creating Microbiomes to Fight Cancer, ALS, and More – Inside Precision Medicine
Media
June 6, 2025: Eric Soyer, directeur financier Maat Pharma : “demande d’autorisation de mise sur le marché” – Lyon Décideurs (French Only)
Media
June 6, 2025: Biothérapie : le lyonnais MaaT Pharma franchit un cap avec son traitement à base de microbiote – La Tribune (French Only)

See more

Media

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

• December 17, 2024 – MaaT Pharma - Key Opinion Leader Discussion - ASH 2024
Videos
R&D Day 2022 replay
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année

Posters

Posters

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity

Posters
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
Posters
MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
Posters
PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only)
Posters
Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors
Posters
Pooling of faecal material results in standardized and high taxonomic and functional richness microbiotherapy products